Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 10/20 | 0.61 |
| ▸ | ADORA2A | P29274 | 9/20 | 0.55 |
| ▸ | PDE4A | P27815 | 8/20 | 0.55 |
| ▸ | PDE4B | Q07343 | 8/20 | 0.55 |
| ▸ | PDE4C | Q08493 | 8/20 | 0.55 |
| ▸ | PDE4D | Q08499 | 8/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3737350 | 0.89 | ADORA2B (0.71) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL11869626 | 0.82 | ADORA2B (0.61) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL10647729 | 0.82 | ADORA2B (0.61) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL11367607 | 0.80 | MEN1 (0.50) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL9160659 | 0.78 | ADORA2B (0.64) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL11101809 | 0.78 | ADORA2B (0.64) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL10955032 | 0.77 | ADORA2B (0.79) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL10819095 | 0.74 | ADORA2B (0.55) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL11430966 | 0.74 | ADORA2B (0.70) | ADORA2B | |
| SCHEMBL3179304 | 0.74 | PDE4A (0.73) | ADORA2BADORA2APDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0483634-B1 | An aminoglycoside composition having substantially reduced nephrotoxicity induced by the amino glycoside | HOECHST ROUSSEL PHARMA (US) | 1996-01-17 | — | — | EP | claimed |
| US-5272153-A | Method of inhibiting the activity of leukocyte derived cytokines | HOECHST-ROUSSEL PHARMACEUTICALS, INC. (US) | 1993-12-21 | — | — | US | claimed |
| US-5196430-A | 7-(oxoalkyl) 1,3-dialkyl xanthines | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1993-03-23 | — | — | US | claimed |
| EP-0493682-A2 | Use of xanthines for the preparation of a medicament effective for inhibiting the effects of allograft reaction in humans | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1992-07-08 | — | — | EP | claimed |
| EP-0490181-A1 | Use of xanthines for preparation of a medicament having immunosuppressing activity | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1992-06-17 | — | — | EP | claimed |
| EP-0484785-A2 | Use of xanthines for the preparation of a medicament effective for inhibiting the replication of human retroviruses | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1992-05-13 | — | — | EP | claimed |
| EP-0483634-A2 | An aminoglycoside composition having substantially reduced nephrotoxicity induced by the amino glycoside | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1992-05-06 | — | — | EP | claimed |
| EP-0344288-A4 | METHOD OF INHIBITING THE ACTIVITY OF LEUKOCYTE DERIVED CYTOKINES | — | 1992-01-15 | — | — | EP | claimed |
| US-5039666-A | Using 7-oxoalkyl-1,3-dialkyl xanthine compound | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1991-08-13 | — | — | US | claimed |
| US-4965271-A | Method of inhibiting the activity of leukocyte derived cytokines | HOECHST ROUSSEL PHARMACEUTICALS, INC. (US) | 1990-10-23 | — | — | US | claimed |
| EP-0344288-A1 | METHOD OF INHIBITING THE ACTIVITY OF LEUKOCYTE DERIVED CYTOKINES | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1989-12-06 | — | — | EP | claimed |
| WO-1989005145-A1 | METHOD OF INHIBITING THE ACTIVITY OF LEUKOCYTE DERIVED CYTOKINES | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1989-06-15 | — | — | WO | claimed |
| EP-0919544-B1 | Compounds useful for treating allergic and inflammatory diseases | SMITHKLINE BEECHAM CORP (US) | 2003-05-14 | — | — | EP | disclosed |
| US-6420374-B1 | PENTOXIFYLLINE. | FRED HUTCHINSON CANCER RESEARCH CENTER | 2002-07-16 | — | — | US | disclosed |
| US-6420374-B1 | PENTOXIFYLLINE. | FRED HUTCHINSON CANCER RESEARCH CENTER | 2002-07-16 | — | — | US | disclosed |
| EP-0483634-B1 | An aminoglycoside composition having substantially reduced nephrotoxicity induced by the amino glycoside | HOECHST ROUSSEL PHARMA (US) | 1996-01-17 | — | — | EP | disclosed |
| US-4291037-A | PROMOTING THE FLOW OF BLOOD THROUGH SKELETAL MUSCLES VASODILATORS | Wulfing, Johann A. (DE) | 1981-09-22 | — | — | US | disclosed |
| US-4242345-A | VASODILATORS | Wulfing, Johann A. (DE) | 1980-12-30 | — | — | US | disclosed |
| US-4242345-A | VASODILATORS | Wulfing, Johann A. (DE) | 1980-12-30 | — | — | US | disclosed |
| US-4242345-A | VASODILATORS | Wulfing, Johann A. (DE) | 1980-12-30 | — | — | US | disclosed |